ReAlta Life Sciences

ReAlta Life Sciences is a clinical-stage biotechnology company dedicated to harnessing the power of the immune system through the EPICC technology platform, comprising over 160 engineered peptide families, to address life-threatening medical needs. ReAlta Life Sciences leverages billions of years of evolution that enable human astroviruses to suppress components of the innate immune system. This novel class of therapeutics utilizes the dual-targeting approach of viruses to rebalance complement and inflammatory processes within the body. The company’s pipeline is led by RLS-0071, which has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE).